Quince Therapeutics, Inc. (QNCX)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
1.37 USD
+0.03
(2.239%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 1.29 -0.08 (-0.081%) ⇩ (April 17, 2026, 7:59 p.m. EDT) Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:56 p.m. EDT
QNCX has collapsed from a $45 high to sub-$2 lows due to failed Phase 3 trials, a dangerous reverse merger filing, and imminent bankruptcy risks. The temporary price surge is a bounce in distress selling, driven purely by speculative 'lottery ticket' call option flow betting on an improbable strategic wipeout, not fundamental recovery. This is a speculative bet on a lottery ticket, not an investment. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 3.135554 |
| AutoARIMA | 3.141611 |
| MSTL | 3.151487 |
| AutoTheta | 3.305245 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 1.49 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 12.35 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 22,332,090 |
| Forward P/E | -1.17 |
| Beta | 1.33 |
| Previous Name | Cortexyme, Inc. |
| Website | https://www.quincetx.com |
As of April 18, 2026, 11:56 p.m. EDT: Options activity is heavily skewed towards out-of-the-money calls, with significant Open Interest (OI) and volume concentrated at deep OTM strikes ($2.00) for the July expiry and ITM calls at the $0.50 strike across multiple expirations. Put OI is minimal and clustered near parity ($1.50), suggesting limited hedging or naked short exposure relative to the speculative call buying. The IV spread is wide, with 5-day calls showing near-zero implied volatility compared to 10-15% for puts, indicating a risky, asymmetric speculative positioning by traders betting on a high-volatility event drive rather than a sustainable trend.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.8695238 |
| Address1 | 611 Gateway Boulevard |
| Address2 | Suite 273 |
| All Time High | 1,219.8 |
| All Time Low | 0.8 |
| Ask | 1.41 |
| Ask Size | 7 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 21,837,906 |
| Average Daily Volume3 Month | 10,364,911 |
| Average Volume | 10,364,911 |
| Average Volume10Days | 21,837,906 |
| Beta | 1.333 |
| Bid | 1.35 |
| Bid Size | 40 |
| Board Risk | 7 |
| Book Value | -6.409 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.37 |
| Current Ratio | 0.53 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.43 |
| Day Low | 1.28 |
| Display Name | Quince Therapeutics |
| Earnings Timestamp End | 1,778,702,400 |
| Earnings Timestamp Start | 1,778,702,400 |
| Ebitda | -50,287,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.458 |
| Enterprise Value | 23,051,088 |
| Eps Current Year | -11.7 |
| Eps Forward | -1.17 |
| Eps Trailing Twelve Months | -16.8 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.4148 |
| Fifty Day Average Change | -0.044800043 |
| Fifty Day Average Change Percent | -0.031665284 |
| Fifty Two Week Change Percent | -86.952385 |
| Fifty Two Week High | 45.5 |
| Fifty Two Week High Change | -44.13 |
| Fifty Two Week High Change Percent | -0.9698901 |
| Fifty Two Week Low | 0.8 |
| Fifty Two Week Low Change | 0.57 |
| Fifty Two Week Low Change Percent | 0.7125 |
| Fifty Two Week Range | 0.8 - 45.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,557,408,600,000 |
| Float Shares | 14,567,531 |
| Forward Eps | -1.17 |
| Forward P E | -1.1709402 |
| Free Cashflow | -11,183,375 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 38 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03188 |
| Held Percent Institutions | 0.13474 |
| Implied Shares Outstanding | 16,300,796 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,776,038,400 |
| Last Split Factor | 1:10 |
| Long Business Summary | Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California. |
| Long Name | Quince Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 22,332,090 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_266230063 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-19 |
| Net Income To Common | -83,979,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 22,576,601 |
| Number Of Analyst Opinions | 1 |
| Open | 1.37 |
| Operating Cashflow | -41,425,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 415 910 5717 |
| Post Market Change | -0.08130002 |
| Post Market Change Percent | -5.934308 |
| Post Market Price | 1.2887 |
| Post Market Time | 1,776,470,390 |
| Prev Name | Cortexyme, Inc. |
| Previous Close | 1.34 |
| Price Eps Current Year | -0.11709402 |
| Price Hint | 4 |
| Price To Book | -0.2137619 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.494 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.03 |
| Regular Market Change Percent | 2.2388 |
| Regular Market Day High | 1.43 |
| Regular Market Day Low | 1.28 |
| Regular Market Day Range | 1.28 - 1.43 |
| Regular Market Open | 1.37 |
| Regular Market Previous Close | 1.34 |
| Regular Market Price | 1.37 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 2,438,015 |
| Return On Assets | -0.30306 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 16,300,795 |
| Shares Percent Shares Out | 0.2481 |
| Shares Short | 1,382,655 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 829,819 |
| Short Name | Quince Therapeutics, Inc. |
| Short Percent Of Float | 0.2767 |
| Short Ratio | 0.39 |
| Source Interval | 15 |
| State | CA |
| Symbol | QNCX |
| Target High Price | 0.0 |
| Target Low Price | 0.0 |
| Target Mean Price | 0.0 |
| Target Median Price | 0.0 |
| Total Cash | 17,752,000 |
| Total Cash Per Share | 1.089 |
| Total Debt | 18,471,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -16.8 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 16.44115 |
| Two Hundred Day Average Change | -15.071151 |
| Two Hundred Day Average Change Percent | -0.9166725 |
| Type Disp | Equity |
| Volume | 2,438,015 |
| Website | https://www.quincetx.com |
| Zip | 94,080 |